| COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study VJ Hall, S Foulkes, A Saei, N Andrews, B Oguti, A Charlett, E Wellington, ... The Lancet 397 (10286), 1725-1735, 2021 | 802 | 2021 |
| SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN) VJ Hall, S Foulkes, A Charlett, A Atti, EJM Monk, R Simmons, E Wellington, ... The Lancet 397 (10283), 1459-1469, 2021 | 717 | 2021 |
| Protection against SARS-CoV-2 after Covid-19 vaccination and previous infection V Hall, S Foulkes, F Insalata, P Kirwan, A Saei, A Atti, E Wellington, ... New England Journal of Medicine 386 (13), 1207-1220, 2022 | 714 | 2022 |
| Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals C Manisty, AD Otter, TA Treibel, Á McKnight, DM Altmann, T Brooks, ... The Lancet 397 (10279), 1057-1058, 2021 | 446 | 2021 |
| Pre-existing polymerase-specific T cells expand in abortive seronegative SARS-CoV-2 L Swadling, MO Diniz, NM Schmidt, OE Amin, A Chandran, E Shaw, ... Nature 601 (7891), 110-117, 2022 | 393 | 2022 |
| Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose CJ Reynolds, C Pade, JM Gibbons, DK Butler, AD Otter, K Menacho, ... Science 372 (6549), 1418-1423, 2021 | 362 | 2021 |
| Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial O Abani, A Abbas, F Abbas, M Abbas, S Abbasi, H Abbass, A Abbott, ... The Lancet 399 (10325), 665-676, 2022 | 347 | 2022 |
| Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure CJ Reynolds, C Pade, JM Gibbons, AD Otter, KM Lin, D Muñoz Sandoval, ... Science 377 (6603), eabq1841, 2022 | 341 | 2022 |
| Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison M Ainsworth, M Andersson, K Auckland, JK Baillie, E Barnes, S Beer, ... The Lancet Infectious Diseases 20 (12), 1390-1400, 2020 | 329 | 2020 |
| Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial O Abani, A Abbas, F Abbas, M Abbas, S Abbasi, H Abbass, A Abbott, ... The Lancet 399 (10320), 143-151, 2022 | 298 | 2022 |
| COVID-19: Rapid antigen detection for SARS-CoV-2 by lateral flow assay: A national systematic evaluation of sensitivity and specificity for mass-testing T Peto, D Affron, B Afrough, A Agasu, M Ainsworth, A Allanson, K Allen, ... EClinicalMedicine 36, 2021 | 220 | 2021 |
| Discordant neutralizing antibody and T cell responses in asymptomatic and mild SARS-CoV-2 infection CJ Reynolds, L Swadling, JM Gibbons, C Pade, MP Jensen, MO Diniz, ... Science immunology 5 (54), eabf3698, 2020 | 213 | 2020 |
| Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a … R Lazarus, S Baos, H Cappel-Porter, A Carson-Stevens, M Clout, ... The Lancet 398 (10318), 2277-2287, 2021 | 176 | 2021 |
| Extended interval BNT162b2 vaccination enhances peak antibody generation H Parry, R Bruton, C Stephens, C Bentley, K Brown, G Amirthalingam, ... npj Vaccines 7 (1), 14, 2022 | 164 | 2022 |
| Pfizer-BioNTech and Oxford AstraZeneca COVID-19 vaccine effectiveness and immune response amongst individuals in clinical risk groups HJ Whitaker, RSM Tsang, R Byford, NJ Andrews, J Sherlock, PS Pillai, ... Journal of Infection 84 (5), 675-683, 2022 | 141 | 2022 |
| Antibody responses after first and second Covid-19 vaccination in patients with chronic lymphocytic leukaemia H Parry, G McIlroy, R Bruton, M Ali, C Stephens, S Damery, A Otter, ... Blood cancer journal 11 (7), 136, 2021 | 124 | 2021 |
| Heterologous infection and vaccination shapes immunity against SARS-CoV-2 variants CJ Reynolds, JM Gibbons, C Pade, KM Lin, DM Sandoval, F Pieper, ... Science 375 (6577), 183-192, 2022 | 123 | 2022 |
| Prior infection with SARS-CoV-2 boosts and broadens Ad26. COV2. S immunogenicity in a variant-dependent manner R Keeton, SI Richardson, T Moyo-Gwete, T Hermanus, MB Tincho, ... Cell host & microbe 29 (11), 1611-1619. e5, 2021 | 115 | 2021 |
| SARS-CoV-2-specific immune responses and clinical outcomes after COVID-19 vaccination in patients with immune-suppressive disease E Barnes, CS Goodyear, M Willicombe, C Gaskell, S Siebert, T I de Silva, ... Nature Medicine 29 (7), 1760-1774, 2023 | 92 | 2023 |
| Differential immunogenicity of BNT162b2 or ChAdOx1 vaccines after extended-interval homologous dual vaccination in older people H Parry, R Bruton, C Stephens, K Brown, G Amirthalingam, A Otter, ... Immunity & Ageing 18, 1-8, 2021 | 80 | 2021 |
Aine McKnightProfessor of Viral Pathologyכתובת אימייל מאומתת בדומיין qmul.ac.uk